Theranostic Aspects: Treatment of Cancer by Nanotechnology

被引:10
作者
Sarkar, Bidisha [1 ]
Paira, Priyankar [1 ]
机构
[1] VIT Univ, Sch Adv Sci, Dept Chem, Vellore 632014, Tamil Nadu, India
关键词
Anti-cancer; theranostic agents; nanocarriers; cancer; m-RNA; pharmacokinetics; DOUBLE-STRANDED-RNA; DRUG-DELIVERY; CARBON NANOTUBES; BREAST-CANCER; PHASE-I; NANOPARTICLES; LIPOSOMES; DOXORUBICIN; CELLS; CHEMOTHERAPY;
D O I
10.2174/1389557518666171129214336
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Theranostic agents or theranostic imaging as its name suggests is a combination of two terms-'diagnosis' & 'therapy'. Efforts are being made to combine both the terms into clinical formulations. This theranostic imaging is found to be very much significant to complex diseases like cancer and proliferative tumors especially because accurate photocopy for every tumor can be obtained by genomic and proteomic profiling and using such informations in theranostic agents can be constructed or modeled in such a way that it is specific in its action and selective towards the cancer cells only, without causing any adverse effects on the normal tissue cells. By means of nanoplatforms, we can conveniently deliver cancer cell specific targeting ligand or peptide inside the human body. Primary delivery approach comprises of nanoparticles, liposomes, dendrimers, prodrugs, polymersomes, carbon nanotubes and polymeric micelles. Theranostic agents, i.e., therapeutic and diagnostic agents can be physically bound or else they can be bound with polymers which are exclusively designed and this together forms nanocarriers. Hence, the review highlights the advances of nanotechnology that has given us a platform for cancer detection and treatment.
引用
收藏
页码:969 / 975
页数:7
相关论文
共 51 条
  • [1] Liposomes: Applications in medicine
    Banerjee, R
    [J]. JOURNAL OF BIOMATERIALS APPLICATIONS, 2001, 16 (01) : 3 - 21
  • [2] Brandl M, 2001, Biotechnol Annu Rev, V7, P59, DOI 10.1016/S1387-2656(01)07033-8
  • [3] Future challenges for drug delivery research
    Breimer, DD
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (03) : 265 - 268
  • [4] Nanoplatforms for targeted molecular imaging in living subjects
    Cai, Weibo
    Chen, Xiaoyuan
    [J]. SMALL, 2007, 3 (11) : 1840 - 1854
  • [5] Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
    Caponigro, F
    Comella, P
    Budillon, A
    Bryce, J
    Avallone, A
    De Rosa, V
    Ionna, F
    Comella, G
    [J]. ANNALS OF ONCOLOGY, 2000, 11 (03) : 339 - 342
  • [6] From conventional to stealth liposomes a new frontier in cancer chemotherapy
    Cattel, L
    Ceruti, M
    Dosio, F
    [J]. TUMORI, 2003, 89 (03) : 237 - 249
  • [7] Quantum dot bioconjugates for ultrasensitive nonisotopic detection
    Chan, WCW
    Nie, SM
    [J]. SCIENCE, 1998, 281 (5385) : 2016 - 2018
  • [8] Development of cytarabine prodrugs and delivery systems for leukemia treatment
    Chhikara, Bhupender S.
    Parang, Keykavous
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (12) : 1399 - 1414
  • [9] DAKHIL S, 1982, CANCER-AM CANCER SOC, V50, P631, DOI 10.1002/1097-0142(19820815)50:4<631::AID-CNCR2820500403>3.0.CO
  • [10] 2-M